Exploiting the anti-HIV-1 activity of acyclovir

Suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin

Christophe Vanpouille, Andrea Lisco, Andrea Introini, Jean-Charles B. Grivel, Arshi Munawwar, Melanie Merbah, Raymond F. Schinazi, Marco Derudas, Christopher McGuigan, Jan Balzarini, Leonid Margolis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Multiple clinical trials have demonstrated that herpes simplex virus 2 (HSV-2) suppressive therapy using acyclovir (ACV) or valacyclovir in HIV-1/HSV-2-infected persons increased the patient's survival and decreased the HIV-1 load. It has been shown that the incorporation of ACV-monophosphate into the nascent DNA chain instead of dGMP results in the termination of viral DNA elongation and directly inhibits laboratory strains of HIV-1. We evaluated here the anti-HIV activity of ACV against primary HIV-1 isolates of different clades and coreceptor specificity and against viral isolates resistant to currently used drugs, including zidovudine, lamivudine, nevirapine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs), a fusion inhibitor, and two protease inhibitors. We found that, at clinically relevant concentrations, ACV inhibits the replication of these isolates in human tissues infected ex vivo. Moreover, addition of ribavirin, an antiviral capable of depleting the pool of intracellular dGTP, potentiated the ACV-mediated HIV-1 suppression. These data warrant further clinical investigations of the benefits of using inexpensive and safe ACV alone or in combination with other drugs against HIV-1, especially to complement or delay highly active antiretroviral therapy (HAART) initiation in low-resource settings.

Original languageEnglish
Pages (from-to)2604-2611
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number5
DOIs
Publication statusPublished - May 2012
Externally publishedYes

Fingerprint

Acyclovir
Ribavirin
HIV-1
HIV
Pharmaceutical Preparations
Human Herpesvirus 2
valacyclovir
Nevirapine
Reverse Transcriptase Inhibitors
Lamivudine
Zidovudine
Highly Active Antiretroviral Therapy
Viral DNA
Protease Inhibitors
Nucleosides
Antiviral Agents
Clinical Trials
Survival
DNA

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Exploiting the anti-HIV-1 activity of acyclovir : Suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin. / Vanpouille, Christophe; Lisco, Andrea; Introini, Andrea; Grivel, Jean-Charles B.; Munawwar, Arshi; Merbah, Melanie; Schinazi, Raymond F.; Derudas, Marco; McGuigan, Christopher; Balzarini, Jan; Margolis, Leonid.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 5, 05.2012, p. 2604-2611.

Research output: Contribution to journalArticle

Vanpouille, C, Lisco, A, Introini, A, Grivel, J-CB, Munawwar, A, Merbah, M, Schinazi, RF, Derudas, M, McGuigan, C, Balzarini, J & Margolis, L 2012, 'Exploiting the anti-HIV-1 activity of acyclovir: Suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin', Antimicrobial Agents and Chemotherapy, vol. 56, no. 5, pp. 2604-2611. https://doi.org/10.1128/AAC.05986-11
Vanpouille, Christophe ; Lisco, Andrea ; Introini, Andrea ; Grivel, Jean-Charles B. ; Munawwar, Arshi ; Merbah, Melanie ; Schinazi, Raymond F. ; Derudas, Marco ; McGuigan, Christopher ; Balzarini, Jan ; Margolis, Leonid. / Exploiting the anti-HIV-1 activity of acyclovir : Suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 5. pp. 2604-2611.
@article{3bdbc351092e4d199800fae1ebce9871,
title = "Exploiting the anti-HIV-1 activity of acyclovir: Suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin",
abstract = "Multiple clinical trials have demonstrated that herpes simplex virus 2 (HSV-2) suppressive therapy using acyclovir (ACV) or valacyclovir in HIV-1/HSV-2-infected persons increased the patient's survival and decreased the HIV-1 load. It has been shown that the incorporation of ACV-monophosphate into the nascent DNA chain instead of dGMP results in the termination of viral DNA elongation and directly inhibits laboratory strains of HIV-1. We evaluated here the anti-HIV activity of ACV against primary HIV-1 isolates of different clades and coreceptor specificity and against viral isolates resistant to currently used drugs, including zidovudine, lamivudine, nevirapine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs), a fusion inhibitor, and two protease inhibitors. We found that, at clinically relevant concentrations, ACV inhibits the replication of these isolates in human tissues infected ex vivo. Moreover, addition of ribavirin, an antiviral capable of depleting the pool of intracellular dGTP, potentiated the ACV-mediated HIV-1 suppression. These data warrant further clinical investigations of the benefits of using inexpensive and safe ACV alone or in combination with other drugs against HIV-1, especially to complement or delay highly active antiretroviral therapy (HAART) initiation in low-resource settings.",
author = "Christophe Vanpouille and Andrea Lisco and Andrea Introini and Grivel, {Jean-Charles B.} and Arshi Munawwar and Melanie Merbah and Schinazi, {Raymond F.} and Marco Derudas and Christopher McGuigan and Jan Balzarini and Leonid Margolis",
year = "2012",
month = "5",
doi = "10.1128/AAC.05986-11",
language = "English",
volume = "56",
pages = "2604--2611",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Exploiting the anti-HIV-1 activity of acyclovir

T2 - Suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin

AU - Vanpouille, Christophe

AU - Lisco, Andrea

AU - Introini, Andrea

AU - Grivel, Jean-Charles B.

AU - Munawwar, Arshi

AU - Merbah, Melanie

AU - Schinazi, Raymond F.

AU - Derudas, Marco

AU - McGuigan, Christopher

AU - Balzarini, Jan

AU - Margolis, Leonid

PY - 2012/5

Y1 - 2012/5

N2 - Multiple clinical trials have demonstrated that herpes simplex virus 2 (HSV-2) suppressive therapy using acyclovir (ACV) or valacyclovir in HIV-1/HSV-2-infected persons increased the patient's survival and decreased the HIV-1 load. It has been shown that the incorporation of ACV-monophosphate into the nascent DNA chain instead of dGMP results in the termination of viral DNA elongation and directly inhibits laboratory strains of HIV-1. We evaluated here the anti-HIV activity of ACV against primary HIV-1 isolates of different clades and coreceptor specificity and against viral isolates resistant to currently used drugs, including zidovudine, lamivudine, nevirapine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs), a fusion inhibitor, and two protease inhibitors. We found that, at clinically relevant concentrations, ACV inhibits the replication of these isolates in human tissues infected ex vivo. Moreover, addition of ribavirin, an antiviral capable of depleting the pool of intracellular dGTP, potentiated the ACV-mediated HIV-1 suppression. These data warrant further clinical investigations of the benefits of using inexpensive and safe ACV alone or in combination with other drugs against HIV-1, especially to complement or delay highly active antiretroviral therapy (HAART) initiation in low-resource settings.

AB - Multiple clinical trials have demonstrated that herpes simplex virus 2 (HSV-2) suppressive therapy using acyclovir (ACV) or valacyclovir in HIV-1/HSV-2-infected persons increased the patient's survival and decreased the HIV-1 load. It has been shown that the incorporation of ACV-monophosphate into the nascent DNA chain instead of dGMP results in the termination of viral DNA elongation and directly inhibits laboratory strains of HIV-1. We evaluated here the anti-HIV activity of ACV against primary HIV-1 isolates of different clades and coreceptor specificity and against viral isolates resistant to currently used drugs, including zidovudine, lamivudine, nevirapine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs), a fusion inhibitor, and two protease inhibitors. We found that, at clinically relevant concentrations, ACV inhibits the replication of these isolates in human tissues infected ex vivo. Moreover, addition of ribavirin, an antiviral capable of depleting the pool of intracellular dGTP, potentiated the ACV-mediated HIV-1 suppression. These data warrant further clinical investigations of the benefits of using inexpensive and safe ACV alone or in combination with other drugs against HIV-1, especially to complement or delay highly active antiretroviral therapy (HAART) initiation in low-resource settings.

UR - http://www.scopus.com/inward/record.url?scp=84860200702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860200702&partnerID=8YFLogxK

U2 - 10.1128/AAC.05986-11

DO - 10.1128/AAC.05986-11

M3 - Article

VL - 56

SP - 2604

EP - 2611

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -